IP Library Granted Patent US 12,599,579
Granted Patent B2
US 12,599,579 · App. 19/261,853 · Granted Apr 14, 2026

Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids

Inventors: Gary Millet (Salt Lake City, UT); Ryan Lowery (Tampa, FL); Jacob Wilson (Tampa, FL); Terry Lacore (Melissa, TX)
Assignee: AXCESS GLOBAL SCIENCES, LLC
A61K31/19A61K9/0053A61K31/522A61P3/04A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,599,579
App. No.
19/261,853
Granted
Apr 14, 2026
Kind
B2
Abstract

Compositions and methods for administering ketone bodies to a subject include a ketone body or ketone body precursor complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

Claims (31)

1 . A composition for administering ketone bodies to a subject, comprising:

a ketone body component including a ketone body, ketone body precursor, or combination thereof; and

an amino acid component including at least one amino acid,

wherein at least a portion of the ketone body component is complexed with and/or coupled to at least a portion of the at least one amino acid component.

2 . The composition of claim 1 , wherein the composition comprises a complex of the ketone body component and the amino acid component.

3 . The composition of claim 1 , wherein the composition comprises a compound of, including a covalent bond between, the ketone body component and the amino acid component.

4 . The composition of claim 1 , wherein the amino acid component includes at least one amino acid selected from the group consisting of leucine, lysine, arginine, histidine, ornithine, creatine, agmatine, citrulline, isoleucine, valine, glutamine, tryptophan, tyrosine, phenylalanine, glycine, beta-alanine, proline, methionine, threonine, and taurine.

5 . The composition of claim 1 , wherein the ketone body component includes at least one of beta-hydroxybutyrate or acetoacetate in acid, salt and/or ester form.

6 . The composition of claim 1 , wherein the ketone body component includes R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, and wherein the composition is enriched with the R-beta-hydroxybutyrate relative to the S-beta-hydroxybutyrate.

7 . The composition of claim 1 , wherein the ketone body component includes greater than approximately 90% R-beta-hydroxybutyrate and less than approximately 10% S-beta-hydroxybutyrate, or greater than approximately 95% R-beta-hydroxybutyrate and less than approximately 5% S-beta-hydroxybutyrate, or greater than approximately 99% R-beta-hydroxybutyrate and less than approximately 1% S-beta-hydroxybutyrate.

8 . The composition of claim 1 , wherein the ketone body precursor includes 1,3-butanediol or ester thereof.

9 . The composition of claim 1 , wherein the ketone body precursor includes at least one medium chain fatty acid or ester thereof.

10 . The composition of claim 1 , wherein the composition provides a dose of from approximately 0.1 g to approximately 50 g of the ketone body component.

11 . The composition of claim 1 , wherein the composition provides a dose of from about 0.1 g to about 20 g of the ketone body component.

12 . The composition of claim 1 , wherein the composition provides a dose of from about 10 g to about 30 g of the ketone body component.

13 . The composition of claim 1 , wherein the composition provides a dose of from approximately 0.5 g to approximately 10 g of the amino acid component.

14 . The composition of claim 1 , wherein the composition provides a dose of from approximately 0.5 g to approximately 2 g of the amino acid component.

15 . The composition of claim 1 , further comprising at least one additive selected from the group consisting of butyrate, butyric acid, tributyrin, short-chain fatty acids, esters of short-chain fatty acids, berberine, berberine metabolites, amino acid metabolites, vitamins, minerals, coconut milk powder, flavorings, caffeine, theacrine, colorings, binders, electrolytes, tetrahydrobiopterin, nucleic acids, alpha-ketoglutaric acid, alpha lipoic acid, nutritional co-factors, beta-methyl-beta-hydroxybutyrate, arginine alpha-ketoglutarate, R-alpha lipoic acid, thiamine, NAD+, NADH, riboflavin, FAD+, FADH, riboflavin-5-phosphate, niacin, nicotinic acid, niacinamide, inositol hexanicotinate, pyridoxine, pyridoxal, pyridoxamine, ascorbic acid, ascorbate salts, citric acid, malic acid, sodium benzoate, pyridoxal-5-phosphate, methylcobalamin, cyanocobalamin, adenosylcobalamin, hydroxycobalamin, pantothenic acid, pantetheine, potassium sorbate, acesulfame K, aspartame, sucralose, stevia, monk fruit extract, allulose, prebiotic fibers, xylo-oligosaccharides (XOS), galacto-oligosaccharides (GOS), mannan-oligosaccharides (MOS), isomalto-oligosaccharides (IMO), lipo-oligosaccharides (LOS), xanthan gum, organic gums, thickeners, and suspension agents.

16 . The composition of claim 1 , wherein the ketone body is selected from the group consisting of beta-hydroxybutyric acid, acetoacetic acid, beta-hydroxybutyrate salts, acetoacetate salts, beta-hydroxybutyrate esters, acetoacetate esters, and combinations thereof.

17 . A method of administering ketone bodies to a subject in need thereof comprising administering the composition of claim 1 to the subject, wherein the composition causes or results in at least one of weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

18 . The method of claim 17 , wherein the composition is administered to the subject orally, enterally, parenterally, intravenously, nasally, sublingually, topically, or rectally.

19 . A composition for administering ketone bodies and increasing blood ketone level in a subject, comprising:

a ketone body component including a ketone body, ketone body precursor, or combination thereof, and

an amino acid component including at least one amino acid selected from the group consisting of leucine, lysine, arginine, histidine, ornithine, creatine, agmatine, citrulline, isoleucine, valine, glutamine, tryptophan, tyrosine, phenylalanine, glycine, beta-alanine, proline, methionine, threonine, and taurine;

wherein at least a portion of the ketone body component is complexed with and/or coupled to at least a portion of the at least one amino acid component.

20 . The composition of claim 19 , wherein the ketone body includes at least one of beta-hydroxybutyrate or acetoacetate in acid, salt and/or ester form.

21 . The composition of claim 19 , wherein the ketone body precursor includes at least one of 1,3-butanediol, medium chain fatty acid, or ester thereof.

22 . A composition for administering ketone bodies to a subject in need thereof, comprising:

a ketone body component including a ketone body, ketone body precursor, or combination thereof;

an amino acid component including at least one amino acid selected from the group consisting of leucine, lysine, arginine, histidine, ornithine, creatine, agmatine, citrulline, isoleucine, valine, glutamine, tryptophan, tyrosine, phenylalanine, glycine, beta-alanine, proline, methionine, threonine, and taurine, wherein at least a portion of the ketone body component is complexed with and/or coupled to at least a portion of the at least one amino acid component; and

at least one additive selected from the group consisting of butyrate, butyric acid, tributyrin, short-chain fatty acids, esters of short-chain fatty acids, berberine, berberine metabolites, amino acid metabolites, vitamins, minerals, coconut milk powder, flavorings, caffeine, theacrine, colorings, binders, electrolytes, tetrahydrobiopterin, nucleic acids, alpha- ketoglutaric acid, alpha lipoic acid, nutritional co-factors, beta-methyl-beta-hydroxybutyrate, arginine alpha-ketoglutarate, R-alpha lipoic acid, thiamine, NAD+, NADH, riboflavin, FAD+, FADH, riboflavin-5-phosphate, niacin, nicotinic acid, niacinamide, inositol hexanicotinate, pyridoxine, pyridoxal, pyridoxamine, ascorbic acid, ascorbate salts, citric acid, malic acid, sodium benzoate, pyridoxal-5-phosphate, methylcobalamin, cyanocobalamin, adenosylcobalamin, hydroxycobalamin, pantothenic acid, pantetheine, potassium sorbate, acesulfame K, aspartame, sucralose, stevia, monk fruit extract, allulose, prebiotic fibers, xylo-oligosaccharides (XOS), galacto-oligosaccharides (GOS), mannan-oligosaccharides (MOS), isomalto-oligosaccharides (IMO), lipo-oligosaccharides (LOS), xanthan gum, organic gums, thickeners, and suspension agents.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2025
From: MILLET, GARY; LOWERY, RYAN; WILSON, JACOB; LACORE, TERRY
To: AXCESS GLOBAL SCIENCES, LLC
Reel/Frame 072899/0456 →
Continuity (6)
Continuation In Part 18977541 · Dec 11, 2024
Continuation 18219556 · Jul 7, 2023
Continuation 17367206 · Jul 2, 2021
Continuation In Part 15491924 · Apr 19, 2017
Provisional Application 62324798 · Apr 19, 2016
Related Publication 20250332128A1 · Oct 30, 2025
References Cited (400)
US 2238149A · Aeckerle · 1941 [cited by applicant]
US 2976073A · Russell et al. · 1961 [cited by applicant]
US 4139761A · Obrowski · 1979 [cited by applicant]
US 4224503A · Gijzel et al. · 1980 [cited by applicant]
US 4292499A · Kleinschmidt et al. · 1981 [cited by applicant]
US 4627808A · Hughes · 1986 [cited by applicant]
US 4663166A · Veech · 1987 [cited by applicant]
US 4771074A · Lammerant et al. · 1988 [cited by applicant]
US 4969393A · Mahlich et al. · 1990 [cited by applicant]
US 4997976A · Brunengraber et al. · 1991 [cited by applicant]
US 5093044A · Wretlind et al. · 1992 [cited by applicant]
US 5100677A · Veech · 1992 [cited by applicant]
US 5116868A · Chen et al. · 1992 [cited by applicant]
US 5288512A · Seiden · 1994 [cited by applicant]
US 5292774A · Hiraide et al. · 1994 [cited by applicant]
US 5654266A · Chen et al. · 1997 [cited by applicant]
US 5700670A · Yamagishi et al. · 1997 [cited by applicant]
US 6031000A · Nissen et al. · 2000 [cited by applicant]
US 6207856B1 · Veech · 2001 [cited by applicant]
US 6217915B1 · Luchansky et al. · 2001 [cited by applicant]
US 6232345B1 · Hiraide et al. · 2001 [cited by applicant]
US 6316038B1 · Veech · 2001 [cited by applicant]
US 6323237B1 · Veech · 2001 [cited by applicant]
US 6380244B2 · Martin et al. · 2002 [cited by applicant]
US 6613356B1 · Vlahakos · 2003 [cited by applicant]
US 6706756B1 · Fitzpatrick et al. · 2004 [cited by applicant]
US 6835750B1 · Henderson · 2004 [cited by applicant]
US 7351736B2 · Veech · 2008 [cited by applicant]
US 7807718B2 · Hashim et al. · 2010 [cited by applicant]
US 7891287B2 · Miller · 2011 [cited by applicant]
US 8071641B2 · Weiss et al. · 2011 [cited by applicant]
US 8101653B2 · Veech · 2012 [cited by applicant]
US 8124589B2 · Henderson · 2012 [cited by applicant]
US 8344896B2 · Ozanne · 2013 [cited by applicant]
US 8426468B2 · Henderson · 2013 [cited by applicant]
US 8642654B2 · Clarke et al. · 2014 [cited by applicant]
US 8748400B2 · Henderson · 2014 [cited by applicant]
US 9138420B2 · D'Agostino et al. · 2015 [cited by applicant]
US 9186340B2 · Andrews et al. · 2015 [cited by applicant]
US 9211275B2 · Clarke et al. · 2015 [cited by applicant]
US 9435566B2 · Hill et al. · 2016 [cited by applicant]
US 9675577B2 · D'Agostino et al. · 2017 [cited by applicant]
US 9717767B2 · Carpenter et al. · 2017 [cited by applicant]
US 9795580B2 · Weeber et al. · 2017 [cited by applicant]
US 9808481B2 · Ritter et al. · 2017 [cited by applicant]
US 9925164B1 · Hashim · 2018 [cited by applicant]
US 9957246B2 · Stinchcomb et al. · 2018 [cited by applicant]
US 10022409B2 · Carpenter et al. · 2018 [cited by applicant]
US 10051880B2 · Clarke et al. · 2018 [cited by applicant]
US 10088197B2 · Hamagami et al. · 2018 [cited by applicant]
US 10154982B2 · Clarke et al. · 2018 [cited by applicant]
US 10245242B1 · Millet · 2019 [cited by applicant]
US 10245243B1 · Millet · 2019 [cited by applicant]
US 10278961B2 · Lowery et al. · 2019 [cited by applicant]
US 10292592B2 · Marshall et al. · 2019 [cited by applicant]
US 10292952B2 · Millet · 2019 [cited by applicant]
US 10407331B2 · Kamito et al. · 2019 [cited by applicant]
US 10512615B1 · Millet · 2019 [cited by applicant]
US 10588876B2 · Millet · 2020 [cited by applicant]
US 10588877B2 · Arnold · 2020 [cited by applicant]
US 10596128B2 · Millet · 2020 [cited by applicant]
US 10596129B2 · Millet · 2020 [cited by applicant]
US 10596130B2 · Millet · 2020 [cited by applicant]
US 10596131B2 · Millet · 2020 [cited by applicant]
US 10660958B2 · Clarke · 2020 [cited by applicant]
US 10736861B2 · Millet · 2020 [cited by applicant]
US 10792269B2 · Hashim · 2020 [cited by applicant]
US 10925843B2 · Millet · 2021 [cited by applicant]
US 10973786B2 · Millet · 2021 [cited by applicant]
US 10980764B1 · D'Agostino et al. · 2021 [cited by applicant]
US 10980772B2 · Millet · 2021 [cited by applicant]
US 11020362B2 · Millet · 2021 [cited by applicant]
US 11026929B2 · Lowery et al. · 2021 [cited by applicant]
US 11033553B2 · Millet · 2021 [cited by applicant]
US 11103470B2 · Millet · 2021 [cited by applicant]
US 11129802B2 · Millet · 2021 [cited by applicant]
US 11173138B2 · Lowery · 2021 [cited by examiner]
US 11185518B2 · Millet · 2021 [cited by applicant]
US 11202769B2 · Millet · 2021 [cited by applicant]
US 11241403B2 · Millet · 2022 [cited by applicant]
US 11690817B2 · Millet · 2023 [cited by applicant]
US 11793778B2 · Millet · 2023 [cited by applicant]
US 11806324B2 · Millet · 2023 [cited by applicant]
US 11944598B2 · Millet · 2024 [cited by applicant]
US 11950616B2 · Millet · 2024 [cited by applicant]
US 11969411B2 · Lowery et al. · 2024 [cited by applicant]
US 12186297B2 · Millet · 2025 [cited by applicant]
US 12251362B2 · Lowery et al. · 2025 [cited by applicant]
US 12350243B2 · Millet · 2025 [cited by examiner]
US 20010014696A1 · Veech · 2001 [cited by applicant]
US 20010018866A1 · Fischer · 2001 [cited by applicant]
US 20010041736A1 · Veech · 2001 [cited by applicant]
US 20020013339A1 · Martin et al. · 2002 [cited by applicant]
US 20020124370A1 · Deckert et al. · 2002 [cited by applicant]
US 20030022937A1 · Veech · 2003 [cited by applicant]
US 20040126366A1 · Kaddurah-Daouk et al. · 2004 [cited by applicant]
US 20040138293A1 · Werner et al. · 2004 [cited by applicant]
US 20040266872A1 · Veech · 2004 [cited by applicant]
US 20050129783A1 · McCleary et al. · 2005 [cited by applicant]
US 20050169968A1 · Elmaleh et al. · 2005 [cited by applicant]
US 20060165777A1 · Solomon et al. · 2006 [cited by applicant]
US 20060275253A1 · Ushida et al. · 2006 [cited by applicant]
US 20070029913A1 · Chen · 2007 [cited by applicant]
US 20070135376A1 · Henderson · 2007 [cited by applicant]
US 20070179197A1 · Henderson · 2007 [cited by applicant]
US 20080058416A1 · Greenwood et al. · 2008 [cited by applicant]
US 20080287372A1 · Henderson · 2008 [cited by applicant]
US 20090131475A1 · Uesugi et al. · 2009 [cited by applicant]
US 20090253781A1 · Veech · 2009 [cited by applicant]
US 20090306221A1 · Guy et al. · 2009 [cited by applicant]
US 20090325984A1 · Costentin et al. · 2009 [cited by applicant]
US 20100041751A1 · Henderson · 2010 [cited by applicant]
US 20100056631A1 · Hisamura et al. · 2010 [cited by applicant]
US 20100113494A1 · Hu et al. · 2010 [cited by applicant]
US 20100197758A1 · Andrews et al. · 2010 [cited by applicant]
US 20100210726A1 · Kuriyama · 2010 [cited by applicant]
US 20100298294A1 · Clarke et al. · 2010 [cited by applicant]
US 20110111049A1 · Andrews et al. · 2011 [cited by applicant]
US 20110237666A1 · Clarke et al. · 2011 [cited by applicant]
US 20110287114A1 · Johnson · 2011 [cited by applicant]
US 20120053240A1 · Rathmacher et al. · 2012 [cited by applicant]
US 20120071548A1 · Veech · 2012 [cited by applicant]
US 20120171165A1 · Buck et al. · 2012 [cited by applicant]
US 20120202891A1 · Stinchcomb et al. · 2012 [cited by applicant]
US 20130079406A1 · Veech · 2013 [cited by applicant]
US 20130337116A1 · Petralia · 2013 [cited by applicant]
US 20140256808A1 · Henderson · 2014 [cited by applicant]
US 20140329893A1 · Veech · 2014 [cited by applicant]
US 20140350105A1 · D'Agostino et al. · 2014 [cited by applicant]
US 20140352728A1 · Svensson · 2014 [cited by applicant]
US 20150018415A1 · Veech · 2015 [cited by applicant]
US 20150063140A1 · Yi et al. · 2015 [cited by applicant]
US 20150065571A1 · Clarke et al. · 2015 [cited by applicant]
US 20150132280A1 · Lopez et al. · 2015 [cited by applicant]
US 20150144074A1 · Fujimoto et al. · 2015 [cited by applicant]
US 20150320809A1 · Carpenter et al. · 2015 [cited by applicant]
US 20150363750A1 · Svensson et al. · 2015 [cited by applicant]
US 20160067207A1 · D'Agostino et al. · 2016 [cited by applicant]
US 20160193173A1 · Clarke et al. · 2016 [cited by applicant]
US 20160256411A1 · Aung-Din · 2016 [cited by applicant]
US 20160263071A1 · Borges et al. · 2016 [cited by applicant]
US 20160272603A1 · Kravchenko et al. · 2016 [cited by applicant]
US 20170020844A1 · Galinski · 2017 [cited by applicant]
US 20170029650A1 · Veling et al. · 2017 [cited by applicant]
US 20170172969A1 · D'Agostino et al. · 2017 [cited by applicant]
US 20170258745A1 · Millet · 2017 [cited by applicant]
US 20170266148A1 · D'Agostino et al. · 2017 [cited by applicant]
US 20170290792A1 · Cavaleri · 2017 [cited by applicant]
US 20170296501A1 · Lowery et al. · 2017 [cited by applicant]
US 20170296520A1 · Lowery et al. · 2017 [cited by applicant]
US 20170298339A1 · Hanson et al. · 2017 [cited by applicant]
US 20170304564A1 · Dehaan et al. · 2017 [cited by applicant]
US 20180020699A1 · Steup · 2018 [cited by applicant]
US 20180021274A1 · Arnold · 2018 [cited by applicant]
US 20180021281A1 · Berger · 2018 [cited by applicant]
US 20180055797A1 · Llosa et al. · 2018 [cited by applicant]
US 20180057846A1 · Llosa et al. · 2018 [cited by applicant]
US 20180195096A1 · Veech et al. · 2018 [cited by applicant]
US 20180214399A1 · Spector et al. · 2018 [cited by applicant]
US 20180238586A1 · Sugatani et al. · 2018 [cited by applicant]
US 20190099394A1 · Ari et al. · 2019 [cited by applicant]
US 20190151267A1 · Millet · 2019 [cited by applicant]
US 20190167613A1 · Millet · 2019 [cited by applicant]
US 20190167614A1 · Millet · 2019 [cited by applicant]
US 20190177673A1 · Llosa et al. · 2019 [cited by applicant]
US 20190183220A1 · Takada · 2019 [cited by applicant]
US 20190183820A1 · Millet · 2019 [cited by applicant]
US 20190183821A1 · Millet · 2019 [cited by applicant]
US 20190191755A1 · Garvey et al. · 2019 [cited by applicant]
US 20190209501A1 · Tinsley, M et al. · 2019 [cited by applicant]
US 20190255028A1 · Lowery et al. · 2019 [cited by applicant]
US 20190262293A1 · Millet · 2019 [cited by applicant]
US 20190313682A1 · Nagel · 2019 [cited by applicant]
US 20190321309A1 · Millet · 2019 [cited by applicant]
US 20200030266A1 · Bradley et al. · 2020 [cited by applicant]
US 20200061004A1 · Millet · 2020 [cited by applicant]
US 20200078973A1 · Valeze et al. · 2020 [cited by applicant]
US 20200129463A1 · Lowery et al. · 2020 [cited by applicant]
US 20200140371A1 · Verdin et al. · 2020 [cited by applicant]
US 20200170982A1 · Millet · 2020 [cited by applicant]
US 20200253909A1 · Millet · 2020 [cited by applicant]
US 20200268701A1 · D'Agostino et al. · 2020 [cited by applicant]
US 20200276203A1 · Larocca et al. · 2020 [cited by applicant]
US 20210095867A1 · Gururaja et al. · 2021 [cited by applicant]
US 20210106168A1 · Cingolani et al. · 2021 [cited by applicant]
US 20210205241A1 · Millet · 2021 [cited by applicant]
US 20210393560A1 · Lowery et al. · 2021 [cited by applicant]
US 20220133673A1 · Millet · 2022 [cited by applicant]
US 20220202760A1 · Greenwood et al. · 2022 [cited by applicant]
US 20230072854A1 · Purpura et al. · 2023 [cited by applicant]
US 20230115966A1 · Wells et al. · 2023 [cited by applicant]
US 20230201145A1 · Millet · 2023 [cited by applicant]
US 20230346721A1 · Millet · 2023 [cited by applicant]
US 20240024265A1 · Millet · 2024 [cited by applicant]
US 20240197668A1 · Millet · 2024 [cited by applicant]
US 20250025434A1 · Millet · 2025 [cited by applicant]
CA 2990927A1 · 2018 [cited by applicant]
CN 86108978A · 1987 [cited by applicant]
CN 1256629A · 2000 [cited by applicant]
CN 1347319A · 2002 [cited by applicant]
CN 1104978C · 2003 [cited by applicant]
CN 1184978C · 2005 [cited by applicant]
CN 1972698A · 2007 [cited by applicant]
CN 101674730A · 2010 [cited by applicant]
CN 101678043A · 2010 [cited by applicant]
CN 101969769A · 2011 [cited by applicant]
CN 102164884A · 2011 [cited by applicant]
CN 104224823A · 2014 [cited by applicant]
CN 105050594A · 2015 [cited by applicant]
CN 106038532A · 2016 [cited by applicant]
CN 106459646A · 2017 [cited by applicant]
CN 106858066A · 2017 [cited by applicant]
CN 108253621A · 2018 [cited by applicant]
CN 109480284A · 2019 [cited by applicant]
CN 111655244A · 2020 [cited by applicant]
CN 111867576A · 2020 [cited by applicant]
CN 112262936A · 2021 [cited by applicant]
DE 102017210992A1 · 2019 [cited by applicant]
EP 0008700A1 · 1980 [cited by applicant]
EP 1112711A1 · 2001 [cited by applicant]
EP 1178748A1 · 2002 [cited by applicant]
EP 1827412A1 · 2007 [cited by applicant]
EP 1915144A2 · 2008 [cited by applicant]
EP 2283834A2 · 2011 [cited by applicant]
EP 1755743B1 · 2013 [cited by applicant]
EP 2976073A1 · 2016 [cited by applicant]
EP 3094321A1 · 2016 [cited by applicant]
EP 3366173A2 · 2018 [cited by applicant]
EP 3446045A1 · 2019 [cited by applicant]
FR 2997302A1 · 2014 [cited by applicant]
GB 2391493A · 2004 [cited by applicant]
ID 201701176 · 2017 [cited by applicant]
JP 11060434A · 1999 [cited by applicant]
JP 2002521330A · 2002 [cited by applicant]
JP 2004035417A · 2004 [cited by applicant]
JP 2008127369A · 2008 [cited by applicant]
JP 5030553B2 · 2012 [cited by applicant]
JP 2015042644A · 2015 [cited by applicant]
JP 5690261B2 · 2015 [cited by applicant]
JP 2015514104A · 2015 [cited by applicant]
JP 2015102323A · 2015 [cited by applicant]
JP 2016514725A · 2016 [cited by applicant]
JP 2016121128A · 2016 [cited by applicant]
JP 2017046688A · 2017 [cited by applicant]
JP 2018158897A · 2018 [cited by applicant]
JP 2018158898A · 2018 [cited by applicant]
JP 2018158899A · 2018 [cited by applicant]
JP 2019533010A · 2019 [cited by applicant]
JP 2020502652A · 2020 [cited by applicant]
JP 2020527583A · 2020 [cited by applicant]
JP 2021504476A · 2021 [cited by applicant]
JP 2021506294A · 2021 [cited by applicant]
JP 2021127322A · 2021 [cited by applicant]
JP 2021193945A · 2021 [cited by applicant]
RU 2345546C2 · 2009 [cited by applicant]
WO 8703808A1 · 1987 [cited by applicant]
WO 9841200A1 · 1998 [cited by applicant]
WO 0004895A2 · 2000 [cited by applicant]
WO 0015216A1 · 2000 [cited by applicant]
WO 0069315A1 · 2000 [cited by applicant]
WO 0370823A2 · 2003 [cited by applicant]
WO 2004108740A1 · 2004 [cited by applicant]
WO 2005077348A1 · 2005 [cited by applicant]
WO 2005107724A1 · 2005 [cited by applicant]
WO 2006029577A1 · 2006 [cited by applicant]
WO 2006061624A1 · 2006 [cited by applicant]
WO 2007115282A2 · 2007 [cited by applicant]
WO 2007138322A1 · 2007 [cited by applicant]
WO 2008005818A1 · 2008 [cited by applicant]
WO 2008021394A2 · 2008 [cited by applicant]
WO 2008024408A2 · 2008 [cited by applicant]
WO 2009089144A1 · 2009 [cited by applicant]
WO 2010021766A1 · 2010 [cited by applicant]
WO 2010104595A1 · 2010 [cited by applicant]
WO 2011101171A1 · 2011 [cited by applicant]
WO 2012019295A1 · 2012 [cited by applicant]
WO 2012024611A1 · 2012 [cited by applicant]
WO 2013057506A1 · 2013 [cited by applicant]
WO 2013150153A1 · 2013 [cited by applicant]
WO 2014153415A2 · 2014 [cited by applicant]
WO 2014153416A1 · 2014 [cited by applicant]
WO 2015063140A1 · 2015 [cited by applicant]
WO 2015071811A1 · 2015 [cited by applicant]
WO 2015156865A1 · 2015 [cited by applicant]
WO 2016123229A1 · 2016 [cited by applicant]
WO 2016149687A1 · 2016 [cited by applicant]
WO 2017156446A1 · 2017 [cited by applicant]
WO 2017165443A1 · 2017 [cited by applicant]
WO 2017165445A1 · 2017 [cited by applicant]
WO 2017182664A1 · 2017 [cited by applicant]
WO 2017184788A1 · 2017 [cited by applicant]
WO 2017208217A2 · 2017 [cited by applicant]
WO 2018055388A1 · 2018 [cited by applicant]
WO 2018089863A1 · 2018 [cited by applicant]
WO 2018114309A1 · 2018 [cited by applicant]
WO 2018132189A1 · 2018 [cited by applicant]
WO 2018175879A1 · 2018 [cited by applicant]
WO 2018187324A1 · 2018 [cited by applicant]
WO 2018187852A1 · 2018 [cited by applicant]
WO 2019018683A1 · 2019 [cited by applicant]
WO 2019099531A1 · 2019 [cited by applicant]
WO 2019104082A1 · 2019 [cited by applicant]
WO 2019108683A1 · 2019 [cited by applicant]
WO 2019118624A1 · 2019 [cited by applicant]
WO 2019200132A1 · 2019 [cited by applicant]
WO 2019204148A1 · 2019 [cited by applicant]
WO 2019237152A1 · 2019 [cited by applicant]
WO 2019237185A1 · 2019 [cited by applicant]
WO 2020041871A1 · 2020 [cited by applicant]
WO 2020092451A1 · 2020 [cited by applicant]
WO 2020257055A1 · 2020 [cited by applicant]
WO 2021178547A1 · 2021 [cited by applicant]
WO 2022040644A2 · 2022 [cited by applicant]
WO 2022232469A1 · 2022 [cited by applicant]
Kim Do Young et al., “Ketone bodies are protective against oxidative stress in neocortical neurons,” Journal of Neurochemistry, vol. 101, Issue 5, Jun. 1, 2007, pp. 1316-1326. [cited by applicant]
Kirsch, Jr et al. “Butanediol Induced Ketosis Increases Tolerance to Hypoxia in the Mouse.” Stroke. 1980. vol. 11, No. 5, pp. 506-513. [cited by applicant]
Kossoff, Eric H. et al. “Optimal Clinical Management of Children Receiving the Ketogenic Diet: Recommendations of the International Ketogenic Diet Study Group.” Epilepsia, Feb. 2009; 50(2):304-17. Epub Sep. 23, 2008. [cited by applicant]
Krotkiewski, “Value of VLCD Supplementation with Medium Chain Triglycerides”, Int J Obes Relat Metab Disord, Sep. 2001, 25 (9), pp. 1393-1400. [cited by applicant]
Lang Chaochun, “Healthy fitness and exercise prescription”, Nov. 30, 2013, p. 201. [cited by applicant]
Lannotti et al., “Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice”, Br J Pharmacol, May 2019, vol. 176, No. 10, pp. 1568-1584. [cited by applicant]
Lee, S. et al. Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements, 2020, Pharmaceutics, 12(68): 1-20 (Year: 2020). [cited by applicant]
Lile et al. Drug Alcohol Depend. 2012, 122 (1-2), 61-69. [cited by applicant]
Lincoln et al. Archives of Biochemistry and Biophysics 1987, 259 (1), 149-156. [cited by applicant]
Lonza, Duocap Capsules, Feb. 16, 2018, https ://web .archive .org/web/20180216001656/https://www.capsugel.com/consumer-health-nutrition-products/duocap-capsules (Year: 2018). [cited by applicant]
Luis Villasenor, “Supplements and Ketogenic Diets—Facts and Myths”, Retrieved from https://www.ketogains.com/2015/09/supplements-and-ketogenic-diets-facts-and-myths/, Sep. 18, 2015, pp. 15. [cited by applicant]
Lytra. G. et al., “Distribution and Organoleptic Impact of Ethyl 3-Hydroxybutanoate Enantiomers in Wine,” J. Agric. Food Chem, vol. 63, Issue 48, 2015, pp. 10484-10491. [cited by applicant]
Maalouf Met al., “Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation,” Neuroscience, New York, NY, US, vol. 145, Issue 1, Mar. … [cited by applicant]
Maalouf Met al., “The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies,” Brain Research Reviews, Elsevier, NL, vol. 59, No. 2, Mar. 1, 2009, pp. 293-315. [cited by applicant]
Maguire et al., “Gut dysbiosis, leaky gut, and intestinal epithelial proliferation in neurological disorders: towards the development of a new therapeutic using amino acids, prebiotics, probiotics, and postbiotics”, Rev… [cited by applicant]
Malo, M. S. et al., Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota, 2010, Gut, 59, 1476-1484 (Year: 2010). [cited by applicant]
Mangels D.R. et al., “Catechins as Potential Mediators of Cardiovascular Health”, Translational Sciences, vol. 37, No. 5, May 1, 2017, pp. 757-763. [cited by applicant]
Maroni, A. et al. Enteric coatings for colonic drug delivery: state of the art, 2017, Expert Opinion on Drug Delivery, 14 (9): 1027-1029 (Year: 2017). [cited by applicant]
McFarland, L. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review, 2014, BMJ Open, 4(8): 1-18 (Year: 2014). [cited by applicant]
Murray, Andrew J., et al. “Novel ketone diet enhances physical and cognitive performance”, The FASEB Journal, No. Dec. 30, 2016. [cited by applicant]
National Center for Biotechnology Information. PubChem Compound Summary for CID 441, 3-Hydroxybutyric acid, https://pubchem.ncbi.nlm.nih.gov/compound/3-Hydroxybutyric-acid. (Year: 2005). [cited by applicant]
Newman et al. “B-Hydroxybutyrate: A Signaling Metabolite”, Annu Rev Nutr., Aug. 21, 2017, pp. 1-30. [cited by applicant]
Newman et al., “B-hydroxybutyrate: Much more than a metabolite”, Diabetes Res Clin Pract., Nov. 2014. [cited by applicant]
Non-Final Rejection Mailed on Sep. 9, 2020 for U.S. Appl. No. 16/783,956. [cited by applicant]
Nova Max Plus Glucose and Ketone Testing with One Monitor. Downloaded Apr. 1, 2015. http://www.novacares.com/nova-max-plus/. [cited by applicant]
O'Mailey et al., Appl. Physiol. Nutr. Metab. 42: 1031-1035 (2017) Published at www.NRCRESEARCHPRESS.com/ APNM on Jul. 27, 2017. [cited by applicant]
O'Meara, Cyndi, Changing Habits, Ketosis—Can we achieve it in a pill?, https://changinghabits. com.au/ketosis-can- we-achieve-it-in-a-pill/, 12 pages, (Jan. 13, 2017). [cited by applicant]
Office Action received for European Patent Application No. 17786592.0, mailed on Jun. 17, 2022, 7 pages. [cited by applicant]
Office Action received for European Patent Application No. 17786592.0, mailed on Sep. 25, 2020, 7 pages. [cited by applicant]
Office Action received for European Patent Application No. 19788264.0, mailed on Mar. 13, 2024, 5 pages. [cited by applicant]
Office Action received for European Patent Application No. 19880284.5, mailed on Nov. 9, 2023, 5 pages. [cited by applicant]
Office Action received for European Patent Application No. 20805593.9, mailed on Dec. 22, 2023, 7 pages. [cited by applicant]
Paraxanthine-Pubchem—2023 (Year: 2023). [cited by applicant]
Parker, Steve, “Ketogenic Mediterraanean Diet: Version 2.3,” Nov. 23, 2010, pp. 1-3. (Year: 2010). [cited by applicant]
Partial supplementary European search report (EPO Form 1507US) issued by the European Patent Office on Sep. 21, 2016 for corresponding European Application No. 14770025.6. [cited by applicant]
Patel, R. et al. Therapeutic Use of Prebiotics, Probiotics, and Postbiotics to Prevent Necrotizing Enterocolitis: What is the Current Evidence? 2014, Clinics in Perinatology, 40(1): 11-25 (Year: 2014). [cited by applicant]
Pete J Cox et al., “Acute nutritional ketosis: implications for exercise performance and metabolism,” Extreme Physiology & Medicine, vol. 3, Issue 1, Dec. 1, 2014, pp. 1-9. [cited by applicant]
Precision Xtra vs. NovaMax Plus: Ketone Meter Evaluation. Jimmy Moore's Livin′ La Vida Low Garb Blog. Downloaded Apr. 1, 2015. http://livinlavidalowcarb.com/blog/precision-xtra-vs-novamax-plus-ketone-meter-evaluation/15… [cited by applicant]
Pubchem, “Acetoacetic acid” Electronic Resource: https://pubchem.ncbi.nim.nih.gov/compound/Acetoacetic-acid, Retrieved on Sep. 3, 2019. [cited by applicant]
Rho et al. “Acetoacetate, Acetone, and Dibenzylamine (A Contaminant In L-(+)-Beta-Hydroxybutyrate) Exhibit Direct Anticonvulsant Actions In Vivo”, Epilepsia, Raven Press Ltd, New York, US, vol. 43, No. 4, Apr. 1, 2002 (… [cited by applicant]
Riccio et al. The human gut microbiota is neither an organ nor a commensal, 2020, FEBS Letters, 594(20): 3262-3271 (Year: 2020). [cited by applicant]
Rich A.J., “Ketone Bodies as Substrates,” Proceedings of the Nutrition Society (1990), vol. 49, 361-373. [cited by applicant]
Robson et al. Expert Opin. Drug Saf. (2011), vol. 10, pp. 675-685 (Year: 2011). [cited by applicant]
Roeder, Lois M., et al. The Effects of Ketone Bodies, Bicarbonate, and Calcium on Hepatic Mitochondrial Ketogenesis. Archives of Biochemistry and Biophysics, vol. 217, No. 2, Sep. pp. 460-467, 1982. [cited by applicant]
Rogers GB et al. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways, 2016, Molecular Psychiatry, 21: 738-748 (Year: 2016). [cited by applicant]
Sajewicz et al. In Journal of Liquid Chromatography & Related Technologies, 33:1047-1057 (2010) (Year: 2010). [cited by applicant]
Sanchez, J. I. et al. Arabinoxylan-oligosaccharides (AXOS) affect the protein/carbohydrate fermentation balance and microbial population dynamics of the Simulator of Human Intestinal Microbial Ecosystem, 2009, Microbial… [cited by applicant]
Sara, How do you know which product is right for you? How to choose exogenous ketones, https://ketosupplements.co.uk/how-to-choose-exogenous-ketones/, 10 pages, (Sep. 25, 2017). [cited by applicant]
Search Report and Written Opinion issued by the Intellectual Property Office of Singapore on Apr. 18, 2016 for corresponding Singapore Application No. 11201506780R. [cited by applicant]
Serum Ketones Test. MedlinePlus Medical Encyclopedia. Downloaded Apr. 1, 2015. http://www.nlm.nih.gov/medlineplus/ency/article/003498.htm. [cited by applicant]
A New Toy Measuring Blood Ketones. Diet Doctor, Aug. 21, 2012. Dowloaded Apr. 1, 2015. http://www.dietdoctor.com/a-new-toy-measuring-blood-ketoones. [cited by applicant]
Allendorfer et al., “Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy”, Epilepsy Behav, May 2017, vol. 70, pp. 349-354. [cited by applicant]
Amazon, “Perfect Keto Perform Pre Workout Powder—Bum Fat for Fuel Energy Supplement Drink Mix for Men and Women—Keto Friendly with Ketone Salts, BCAA, Nitric Oxide & MCT”, Sep. 25, 2017 entire document especially p. 1 R… [cited by applicant]
Anonymous: “Strawberry Pineapple Flavour Pre-Exertion Performance Optimizer”, MINTEL, Database accession No. 5661617, 2018, pp. 4. [cited by applicant]
Arendash et al. “Caffeine and Coffee as Therapeutics Against Alzheimer's Disease”, Journal of Alzheimer's Disease 20, 2010, S117-S126. [cited by applicant]
Arnold, Instant Ketosis?, (2013), Aug. 4, 2013 (retrieved on Apr. 21, 2017), p. 1-3. Retrieved from the internet; URL: <http://patrickarnoldblog.com/instant-ketosis/. (Year: 2013). [cited by applicant]
Bala et al. Drug Invention Today. Jun. 1, 2018;10(6), 929-931. [cited by applicant]
Bastin et al., “Salt Slection and Optimisation Procedures for Pharmaceutical New Chemical Entities”, American Chemical Society and The Royal Society of Chemistry, vol. 4, No. 5, 2000, pp. 427-435. [cited by applicant]
Blazquez et al. Journal of Neurochemistry, 1999, vol. 72 No. 4, pp. 1759-1768. (Year: 1999). [cited by applicant]
Budin. N. et al., “Efficient synthesis of the ketone body ester (R)-3-hydroxybutyryl-(R)-3-hydroxybutyrate and its (S, S) enantiomer,” Bioorganic Chemistry, vol. 80, Oct. 2018, pp. 560-564. [cited by applicant]
Clarke, et al., Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. Aug. 2012; 63(3):401-8. [cited by applicant]
Craciun, S. et al. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme, 2012, PNAS, 109(52): 21307-21312 (Year: 2012). [cited by applicant]
Cresci, G. et al., Lactobacillus GG and Tributyrin Supplementation Reduce Antibiotic-Induced Intestinal Injury, 2013, Journal of Parenteral and Enteral Nutrition, 37(6), 1-20 (Year: 2013). [cited by applicant]
D'Souza et al. Neuropsychopharmacology 2004, 29, 1558-1572. [cited by applicant]
Daniells, Stephen, ‘This is caffeine-evolved’: Ingenious Ingredients co-founder talks up potential of paraxanthine,′ Nov. 3, 2021, 2 pages, retrieved from https://www.nutraingredients-usa.com/Article/2021/11/03/This-is-… [cited by applicant]
Database GNPD Mintel, Sep. 29, 2016, anonymous, “Blue Lemon Ice Advanced Formula”, XP093048090, Database accession No. 4315637, pp. 3. [cited by applicant]
Decision to grant received for European Patent Application No. 17786592.0, mailed on Nov. 3, 2023, 2 pages. [cited by applicant]
Dedkova et al. “Role of B-hydroxybutyrate, its polymer poly-b-hydroxybutyrate and inorganic polyphosphate in mammalian health and disease”, Frontiers in Physiology, Jul. 17, 2014, pp. 1-22. [cited by applicant]
Dietary Guidelines Recommendations at https://health.gov/our-work/food-nutrition/2015-2020-dietary-guidelines/ guidelines/ appendix-7/ (2010) (retrieved from the internet Oct. 20, 2020) (Year: 2010). [cited by applicant]
Dolson, Laura. How to Test Your Blood for Ketones. Downloaded Apr. 1, 2015. http://lowcarbdiets.about.com/od/KetogenicDiets/a/How-to-Test-Blood-For-Ketones.htm. [cited by applicant]
Energy Times—“Herbal Keto Support”, Jan. 15, 2008 (5 pages). [cited by applicant]
English translation of WO2013057506 accessed form patentscope.wipo.com Jul. 14, 2021. [cited by applicant]
Enhancing Human Performance: Ketones. Blue Sky Fact Finding Meeting, Oct. 24, 2012. [cited by applicant]
European Search Report received for EP Patent Application No. 19880284.5, mailed on Jul. 12, 2022, 11 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 20755289.4, mailed on Oct. 11, 2022, 7 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 20755994.9, mailed on Sep. 21, 2022, 6 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 20805593.9, mailed on Dec. 16, 2022, 9 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 21750261.6, mailed on Feb. 2, 2024, 10 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 21862356.9, mailed on Jul. 1, 2024, 10 pages. [cited by applicant]
Extended European Search Report issued in PCT/US2017021886 dated Oct. 17, 2019. [cited by applicant]
Extended European Search Report pursuant to Rule 62 EPC (EPO Form 1507S) issued on Jan. 24, 2017 for corresponding European Patent Application No. 14770025.6. [cited by applicant]
Extended European Search Report received for EP Patent Application No. 19788264.0, mailed on Dec. 20, 2021, 11 pages. [cited by applicant]
Extended European Search Report received for EP Patent Application No. 20755770.3, mailed on Sep. 1, 2022, 7 pages. [cited by applicant]
First Examination Report for New Zealand Patent Application No. 711433 issued by the New Zealand Intellectual Property Office dated Mar. 10, 2016. [cited by applicant]
First Office Action issued by the Chinese State Intellectual Property Office on Nov. 4, 2016 for corresponding Chinese Patent Application No. 201480016818.0. [cited by applicant]
Grootaert, C. Comparison of prebiotic effects of arabinoxylan oligosaccharides and inulin in a simulator of the human intestinal microbial ecosystem, 2009, FEMS Microbiology Ecology, 69: 231-242 (Year: 2009). [cited by applicant]